Prostate cancer’s clinical complexity stems largely from its heterogeneous nature, where varying cellular characteristics within a single tumor influence disease progression and treatment response. The Gleason score, a pivotal grading system, stratifies prostate cancer aggressiveness, with higher scores correlating with poor prognosis and resistance to conventional therapies. However, non-invasive, reliable preoperative assessments remain elusive, often leading to delayed interventions and suboptimal outcomes.

The research team embarked on a retrospective exploration, integrating conventional MRI modalities — T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) maps — from a robust cohort of 264 patients diagnosed with prostate cancer. These diverse imaging techniques offer complementary insights, capturing structural, cellular, and microenvironmental tumor attributes, essential for comprehensive radiomic analysis.

Central to their approach was the concept of habitat imaging (HI), which partitions tumors into distinct microenvironmental subregions, or habitats, illuminating the spatial variation within the malignancy. This paradigm shift enables the quantification of intratumoral heterogeneity (ITH) via advanced radiomic features extracted from these habitats, transcending traditional whole-tumor analyses that often overlook subtle but clinically significant variations.

The study unfolded through two pivotal tasks. The first task aimed to discriminate between high and low Gleason scores using radiomic signatures derived from the entire tumor and habitat-specific heterogeneity metrics. Employing sophisticated multivariate logistic regression allowed the identification of independent clinical variables to be integrated with radiomic data, culminating in a composite predictive model. This integrative strategy not only enhanced predictive capabilities but also underscored the synergistic potential of combining imaging biomarkers with clinical parameters.

In this initial phase, the cohort was judiciously split into training and validation subsets, ensuring rigorous evaluation protocols. The intratumoral heterogeneity model outperformed traditional radiomics, achieving remarkable area under the curve (AUC) values of 0.892 in training and 0.826 in validation datasets. These metrics underscore the model’s robust discriminatory power, positioning it as a potential game-changer in preoperative risk stratification.

Building upon these insights, the second task concentrated exclusively on patients harboring high-Gleason score tumors, probing the capacity of habitat-based radiomic signatures to foresee the emergence of CRPC within a year following androgen deprivation therapy (ADT). Among 142 patients followed longitudinally, a subset developed CRPC, enabling the evaluation of predictive accuracy through receiver operating characteristic (ROC) curve and decision curve analyses.

Remarkably, the habitat-based heterogeneity model demonstrated superior prediction accuracy with AUC scores of 0.802 and 0.840 across training and testing sets, respectively. These findings highlight the potential of habitat radiomics as an early warning system for therapy resistance, thereby advocating for more personalized, timely interventional strategies.

Such strides in imaging informatics epitomize the broader scientific movement towards personalized oncology. By leveraging non-invasive imaging to capture tumor heterogeneity in vivo, clinicians can foresee aggressive disease courses and tailor therapies accordingly. This reduces the reliance on invasive biopsies and complements molecular diagnostics, deeply enriching the clinical decision-making arsenal.

Furthermore, the implications extend beyond prognostication. Habitat-based MRI radiomics could guide adaptive therapeutic planning, enabling oncologists to monitor intratumoral dynamics and anticipate evolving resistance patterns with unprecedented granularity. This could revolutionize the management of prostate cancer, shifting paradigms from reactive treatments to proactive, precision-based protocols.

Crucial to the study’s success was the meticulous integration of quantitative imaging features with sophisticated statistical modeling. The multivariate logistic regression ensured that the combined model capitalized on orthogonal information streams, capturing both morphological and microenvironmental nuances of tumor biology. This methodological rigor lends credence to the robustness and reproducibility of the findings.

Moreover, the extensive validation framework underscores the translational potential of this technology. By demonstrating consistent predictive performance across independent cohorts, the model positions itself as a viable candidate for clinical trials, and eventually integration into routine diagnostic workflows.

The study also shines a light on the urgent need for standardized radiomic protocols. Variability in MRI acquisition parameters and image preprocessing can significantly affect radiomic feature stability and, by extension, model accuracy. Addressing these technical challenges through harmonization efforts will be pivotal in realizing the full clinical potential of habitat-based radiomics.

Experts herald this study as a testament to the synergy between advanced imaging and computational analytics in unraveling cancer’s intricate heterogeneity. As the oncology community rallies around precision medicine, such pioneering approaches will be instrumental in decoding the complex tumor ecosystem, paving the way for breakthroughs in cancer prognosis and therapeutic management.

In conclusion, this retrospective analysis presents compelling evidence that habitat-based MRI radiomics, through quantification of intratumoral heterogeneity, offers an unparalleled window into the aggressiveness of prostate cancer and its resistance trajectory. As the field advances, these imaging biomarkers could transition from experimental tools to clinical mainstays, dramatically enhancing patient stratification, treatment planning, and ultimately, survival outcomes.

Subject of Research: Prostate cancer; intratumoral heterogeneity; habitat-based MRI radiomics; Gleason score prediction; castration-resistant prostate cancer prediction.

Article Title: Quantification of intratumoral heterogeneity using habitat-based MRI radiomics for predicting high-Gleason scores and castration-resistant PCa: retrospective study.

Article References:
Zhai, CF., Yang, X., Qi, X. et al. Quantification of intratumoral heterogeneity using habitat-based MRI radiomics for predicting high-Gleason scores and castration-resistant PCa: retrospective study. BMC Cancer (2025). https://doi.org/10.1186/s12885-025-15300-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15300-8

Obesity has long been recognized as a critical risk factor for endometrial cancer, with epidemiological studies repeatedly demonstrating a correlation between excess body fat and cancer incidence. However, the heterogeneous nature of adipose tissue calls for a deeper exploration into how different fat compartments impact cancer biology. Visceral adipose tissue, which envelops vital internal organs, exerts complex influences on systemic metabolism and inflammatory processes, far surpassing the effects attributed to subcutaneous fat. The nuances of this adipose depot’s metabolic behavior may hold the key to understanding cancer aggressiveness at a molecular level.

The investigative team based at Haukeland University Hospital and the University of Bergen employed positron emission tomography/computed tomography (PET/CT) imaging to quantitatively assess glucose metabolism within the visceral fat of 274 women diagnosed with endometrial cancer. PET/CT serves as a powerful, non-invasive tool for visualizing metabolic activity in vivo by measuring the uptake of radiolabeled glucose analogues, thus providing a functional map of biological processes within tissues. Their analysis revealed that elevated glucose uptake in visceral adipose tissue correlates strongly with more advanced cancer stages and increased incidence of lymph node involvement.

This pioneering research emphasizes that the volume of visceral fat is not the sole determinant of cancer severity; rather, the metabolic intensity within this fat depot plays a crucial, independent role. Lead author Jostein Sæterstøl, a medical physicist and PhD candidate, highlighted the absence of a strong correlation between fat quantity and metabolic activity. This underscores the importance of evaluating the biological characteristics of adipose tissue, particularly its metabolic output and inflammatory status, to better stratify patient risk and tailor clinical interventions.

Mechanistically, the heightened metabolic activity of visceral fat may exacerbate cancer aggressiveness through several interrelated pathways. Chronic inflammation within adipose tissue results in the secretion of proinflammatory cytokines and free fatty acids, both of which can facilitate tumor proliferation and aid in immune system evasion. Additionally, this inflammatory milieu often induces insulin resistance, creating a systemic environment conducive to cancer progression. Adipokines—a diverse group of signaling molecules released by fat cells—further modulate tumor biology through complex crosstalk between adipose tissue and malignant cells, possibly enhancing metastasis, particularly to regional lymph nodes.

Despite the promising potential of PET/CT-based metabolic assessment of visceral fat, routine clinical adoption remains constrained by technical and biological challenges. The inherently low uptake signal of glucose analogues in adipose tissue poses difficulties in imaging precision, compounded by variability between patients and imaging protocols. Advances such as standardized imaging methodologies, sophisticated quantitative PET analysis, and the integration of artificial intelligence for image segmentation and interpretation offer a vision of future diagnostic refinement. These innovations could enable clinicians to identify high-risk patients earlier, optimize personalized treatment strategies, and monitor disease dynamics with unprecedented accuracy.

Looking forward, the research team plans to expand their investigative framework to enhance the robustness of visceral fat metabolic measurements. They aim to integrate AI-driven segmentation techniques to improve the resolution and reproducibility of PET/CT assessments. Furthermore, probing the relationship between visceral fat metabolism and circulating biomarkers—including cytokines and hormones—may illuminate systemic mechanisms linking metabolic dysfunction to tumor biology. Delving into tumor genomic profiles alongside adipose tissue metabolic states could unravel intricate biological interactions dictating cancer progression.

Another promising avenue involves longitudinal analysis of visceral fat activity to evaluate temporal changes during disease evolution and therapeutic response. Tracking these dynamics might reveal valuable biomarkers for early detection of treatment efficacy or relapse, enhancing clinical decision-making. Such comprehensive studies could ultimately reshape our understanding of how metabolic disorders intersect with oncogenesis, driving forward the development of targeted interventions addressing both metabolic health and cancer control.

This research marks a significant advance in the field of nuclear medicine and oncology, underscoring the importance of metabolic imaging as not merely a tool for tumor visualization but as a window into the tumor microenvironment and systemic factors influencing cancer behavior. The implications extend beyond endometrial cancer, offering a conceptual framework applicable to other obesity-related malignancies where metabolic health profoundly impacts disease outcomes.

The confluence of metabolic science, advanced imaging, and cancer biology exemplifies precision medicine’s future—one where nuanced biological activities within seemingly inert tissues determine prognosis and guide therapy. As nuclear medicine pioneers continue to innovate, harnessing the full power of PET/CT coupled with computational analytics promises to revolutionize cancer diagnostics, prognostication, and treatment personalization, ultimately improving patient survival and quality of life.

In sum, this paradigm-shifting study compels the medical community to look beyond traditional measures of obesity and consider the intricate metabolic activity within fat depots as an independent factor influencing the aggressiveness of endometrial cancer. It opens new frontiers for research, clinical practice, and interdisciplinary collaboration aimed at unraveling and targeting the metabolic underpinnings of cancer progression.

Subject of Research: Metabolic activity of visceral fat and its association with endometrial cancer aggressiveness.

Article Title: High Metabolic Activity of Visceral Fat Linked to Aggressive Endometrial Cancer: A Novel Insight from PET/CT Imaging.

News Publication Date: 5 October 2025.

References:

1. Sæterstøl J, Lavik J, Lunde LP et al. Is Visceral Adipose Tissue Metabolism Linked to Aggressiveness in Endometrial Cancer? Presented at EANM’25 on Sunday 5 October 2025.
2. Fasmer, K.E., Sæterstøl, J., Ljunggren, M.B.S. et al. Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up. BMC Cancer 25, 879 (2025).
3. van den Bosch A. A. S., Pijnenborg J. M. A., Romano A., Winkens B., van der Putten L. J. M., Kruitwagen R. F. P. M., & Werner H. M. J. (2023). The impact of adipose tissue distribution on endometrial cancer: a systematic review. Frontiers in Oncology, 13, Article 1182479.
4. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010-1013.
5. Westerterp M, Hooiveld GJ, van der Kallen CJH, et al. Associations of abdominal subcutaneous and visceral fat with insulin resistance and secretion differ between men and women: The Netherlands Epidemiology of Obesity Study. Metab Syndr Relat Disord.
6. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. Circulation. 2013;128(22):2317-2324.

Keywords: Metabolic disorders, Diabetes, Obesity, Childhood obesity, Cancer, Cancer immunology, Metastasis, Health care